

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/938,669	08/27/2001	Jens Petersen	60117.000004	2508
7590 06/10/2004			EXAMINER	
Stanislaus Aksman			AZPURU, CARLOS A	
Hunton & Williams Suite 1200			ART UNIT	PAPER NUMBER
1900 K Street, N.W.			1615	
Washington, DC 20006			DATE MAILED: 06/10/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/938,669	PETERSEN, JENS			
Office Action Summary	Examiner	Art Unit			
	Carlos A. Azpuru	1615			
The MAILING DATE of this communication		th the correspondence address			
Period for Reply		ONTH(S) EROM			
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, If NO period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by some Any reply received by the Office later than three months after the rearned patent term adjustment. See 37 CFR 1.704(b).	DN. FR 1.136(a). In no event, however, may a n. a reply within the statutory minimum of thir eriod will apply and will expire SIX (6) MON statute, cause the application to become Al	reply be timely filed by (30) days will be considered timely. ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 2	25 May 2004.				
7-1					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with the practice und	der Ex parte Quayle, 1955 C.L	7. 11, 400 0.0. 210.			
Disposition of Claims					
4) Claim(s) 27-42 is/are pending in the application 4a) Of the above claim(s) is/are with 5) Claim(s) is/are allowed. 6) Claim(s) 27-30 and 33-42 is/are rejected. 7) Claim(s) 31 and 32 is/are objected to. 8) Claim(s) are subject to restriction a	ndrawn from consideration.				
Application Papers					
9) The specification is objected to by the Example 10) The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the continuous The oath or declaration is objected to by the	accepted or b) objected to the drawing(s) be held in abeya orrection is required if the drawing	nce. See 37 CFR 1.85(a). (s) is objected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docur 2. Certified copies of the priority docur 3. Copies of the certified copies of the application from the International But * See the attached detailed Office action for a	ments have been received. ments have been received in A priority documents have beer ureau (PCT Rule 17.2(a)).	Application No received in this National Stage			
Attachment(s) 1) Notice of References Cited (PTO-892)		Summary (PTO-413)			
 2) Notice of Draftsperson's Patent Drawing Review (PTO-94-3) Information Disclosure Statement(s) (PTO-1449 or PTO/S Paper No(s)/Mail Date 04082004. 	٠, ١, ١, ١, ١, ١, ١, ١, ١, ١, ١, ١, ١, ١,	(s)/Mail Date Informal Patent Application (PTO-152)			

Application/Control Number: 09/938,669

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of the terminal disclaimers and amendment after final filed 05/25/2004. An information disclosure statement was filed on 04/08/2004.

Response to Arguments

Applicant's arguments with respect to claims 27-42 have been considered but are most in view of the new ground(s) of rejection.

The finality of the last office action is withdrawn.

The following rejection is cited in view of applicant's submission of an information disclosure statement:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 27-30, 33-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Purkait.

Application/Control Number: 09/938,669

Art Unit: 1615

Purkait disclose a soft tissue implant filling material (tissue augmentation) which may be any of several polymers including polyacrylamide (see Abstract). At col. 7, lines 60-67; and col. 8, lines 1-62, Purkait discloses the method of making a soft tissue implant by combining acrylamide and methylene bis acrylamide. The resultant polymer is then filtered in a water alcohol solution. The polymer is not only biocompatible (see col. 3, lines 6-8), but also sterile (see col. 4, lines 27-32), which would meet the limitation of being pyrogen free. Purkait therefore appears to disclose the same tissue augmenting prosthesis and polymer used therein. While Purkait does not disclose the weight percent of polymer or water for this hydrogel, other parameters such as viscosity, and the fact that they are used for the same art recognized purpose (col. 1, lines 20-28; col. 2, lines 28-37) would those of ordinary skill to vary the weight percentage of any polyacrylamide hydrogel used for soft tissue augmentation within an acceptable range for such implants. Indeed, those of ordinary skill would have expected similar tissue augmenting results from the use of the prosthesis disclosed by Purkait. As such, the instant claims would have been obvious given the disclosure of Purkait.

Claims 31-33 are objected to as dependent upon a rejected base claim.

Application/Control Number: 09/938,669

Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlos A. Azpuru whose telephone number is (571) 272-0588. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

са

CARLOS A. AZPURU PRIMARY EXAMINER